Innovent's oncology segment is dedicated to the research, development, and commercialization of innovative therapies for various cancer types. This segment focuses on immuno-oncology and antibody-drug conjugates (ADCs). Key activities include clinical trials for novel cancer treatments, such as sintilimab (TYVYT®), and the development of next-generation IO and ADC platforms. The goal is to improve patient outcomes by providing targeted and effective cancer therapies. The segment leverages advanced technologies in antibody engineering and drug delivery to create innovative solutions for unmet medical needs in oncology. Strategic partnerships enhance the development and commercialization of these therapies.

This segment focuses on developing treatments for metabolic diseases such as diabetes and hypercholesterolemia. Research and development efforts are directed towards innovative therapies like mazdutide, which has shown dual benefits in glycemic control and weight management. Clinical trials are conducted to evaluate the efficacy and safety of these treatments. The segment aims to address the growing global burden of metabolic disorders by providing effective and accessible therapeutic options. The company is committed to investing in innovation and expanding its portfolio of metabolic disease therapies through strategic collaborations and partnerships.

Innovent's immunology segment is focused on developing biologics and biosimilars for the treatment of autoimmune diseases. This includes research and development of adalimumab biosimilars and novel therapies targeting immune-mediated disorders. The segment aims to provide cost-effective and high-quality treatment options for patients with autoimmune conditions. Clinical trials are conducted to demonstrate the efficacy and safety of these therapies. The company leverages its expertise in antibody engineering and manufacturing to develop innovative solutions for unmet medical needs in immunology. Strategic partnerships enhance the development and commercialization of these therapies.